Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
91105 trials found · Page 126 of 4556
-
New immunotherapy MK-1045 targets Hard-to-Treat lymphomas
Disease control Not yet recruitingResearchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that cause…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 06, 2026 16:04 UTC
-
New hope for Tough-to-Treat colon cancer: phase 3 trial launches
Disease control Not yet recruitingColorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine a…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 04, 2026 16:24 UTC
-
New drug targets deadly brain cancer that has returned
Disease control Not yet recruitingBackground: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells. Objective: …
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
New cream shows promise for chronic skin condition
Disease control Not yet recruitingThe main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because …
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated May 05, 2026 11:55 UTC
-
New hope for advanced colon cancer: experimental drug combo enters final testing phase
Disease control Not yet recruitingThis study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall survival prolongation with precemtabart tocen…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo therapy aims to stop head and neck cancer recurrence
Disease control Not yet recruitingA multicenter, randomized, controlled, open-label, Phase II/III clinical trial designed to evaluate the efficacy and safety of postoperative radiotherapy combined with Nimotuzumab,with or without Bemcentinib, in postoperative head and neck squamouscell cancer patients with interm…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated May 07, 2026 14:35 UTC
-
New hope for myelofibrosis patients with anemia: drug combo trial launches
Disease control Not yet recruitingThis is a phase II, multicenter, open-label trial evaluating the safety and efficacy of pacritinib and selinexor in JAK inhibitor naïve patients with anemia and thrombocytopenia.
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Magic mushroom compound may shield cancer patients from chemo nerve pain
Prevention Not yet recruitingTo learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study, psilocybin is being compared to standard supportive care…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Apr 30, 2026 15:50 UTC
-
New hope for kids with leukemia: drug trial targets cancer cells
Disease control Recruiting nowThe aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly …
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:52 UTC
-
Gut bacteria boost could help stop Cancer's return
Disease control Not yet recruitingThis phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell cancer. Pembrolizumab is an immune checkpoint inhibito…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 09, 2026 19:33 UTC
-
New combo therapy aims to beat back aggressive lymphoma
Disease control Not yet recruitingThis phase III trial compares the effect of adding pirtobrutinib to the usual treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) to R-CHOP alone for the treatment of Richter transformation, which is when chronic lymphocytic leukemia or sm…
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
New personalized safety plans aim to curb veteran suicide after hospital discharge
Symptom relief Not yet recruitingVeterans psychiatrically hospitalized face significantly elevated suicide risk, particularly in the three months post-discharge. While Safety Planning is a required component of discharge planning, many safety plans lack personalization thereby reducing their effectiveness. The p…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Apr 26, 2026 19:36 UTC
-
Blood test could spare some cancer patients from harsh chemo
Knowledge-focused Not yet recruitingCIRCULATE-III is an international, multicenter, open-label, randomized phase III trial designed to use ctDNA as a selection criterion for intensification or de-escalation of adjuvant chemotherapy. Eligible patients are randomly assigned to the following treatment groups: * Patie…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:51 UTC
-
New combo therapy aims to boost depression treatment success
Symptom relief Recruiting nowRepetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated May 01, 2026 15:57 UTC
-
Could a special diet boost Crohn's treatment? new study investigates
Disease control Not yet recruitingCrohn's disease (CD) is a chronic inflammatory bowel disease with high recurrence and surgical rates. Mucosal healing is a key therapeutic goal, yet current anti-TNF-α biologics achieve only about 30% mucosal healing. Dietary intervention, particularly the Crohn's Disease Exclusi…
Phase: NA • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New pill combo aims to extend life in tough bile duct cancer
Disease control Not yet recruitingThe object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS). Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-soft…
Phase: PHASE3 • Sponsor: InnoPharmax Inc. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC
-
New hope for lung cancer patients with brain tumors: drug combo trial launches
Disease control Not yet recruitingThis is a prospective, open-label, multi-center, single-arm clinical trial
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated May 07, 2026 14:35 UTC
-
AI and CT scans join forces to catch lung cancer early in latin america
Diagnosis Not yet recruitingProspective study to assess lung cancer screening with low dose CT scan (LDCT) in Latin America (LATAM) and prospectively evaluate chest-XRay analyzed with artificial intelligence (AI) using qXRin (QURE ai) at the initial visit correlating with the findins of the initial LDCT in …
Sponsor: Latin American Consortium for the Lung Cancer Research • Aim: Diagnosis
Last updated May 04, 2026 16:23 UTC
-
New immune booster aims to stop childhood cancer relapse after transplant
Disease control Not yet recruitingA first-in-class adoptive immunotherapy we called ThINKK, for Therapeutic Inducers of Natural Killer (NK) cell Killing, have been designed for use after hematopoietic stem cell transplantation (HSCT), where the proper stimulation of graft-derived NK cells has been shown to preven…
Phase: PHASE1 • Sponsor: Michel Duval • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
Bone-Shifting surgery could heal diabetic wounds and prevent amputations
Disease control Not yet recruitingThe purpose of this study is to evaluate the safety and clinical performance of transverse tibial bone transport in patients with chronic ischemic and diabetic lower extremity ulcers. This study will assess wound healing outcomes and limb preservation in a population with limited…
Phase: NA • Sponsor: Biodynamik, Inc • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC